---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: upLIFT"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: upLIFT. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 62 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence/uplift"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: upLIFT

<a id="heading-3.1.1"></a>

## 3.1.1 upLIFT

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Objectives stated in the ClinicalTrials.gov brief summary

> “The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.1-2"></a>

#### Main objective in the EU Clinical Trials Information System record

> “To evaluate the glycemic efficacy of ersodetug as measured by the number of participants able to achieve a clinically meaningful reduction in continuous glucose requirements compared to baseline.”

Source: [EU Clinical Trials Information System 2024-515447-36-00](https://euclinicaltrials.eu/ctis-public/view/2024-515447-36-00)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-04-16”
> “Primary Completion (Estimated) 2027-09”
> “Study Completion (Estimated) 2027-09”
> “First Posted 2025-03-18”
> “Last Update Posted 2026-09-28”
> “Recruiting”
> “No Results Posted”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.2-2"></a>

#### Planned number of sites and countries in the ClinicalTrials.gov record

> “This study is being conducted at approximately 10-15 study sites in approximately 5 countries.”
> “This study has 13 locations”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.2-3"></a>

#### Study locations by country in the ClinicalTrials.gov record

| Country | Locations listed in the record |
| --- | --- |
| United States | “Chicago, Illinois, United States, 60637”; “Bethesda, Maryland, United States, 20892”; “Boston, Massachusetts, United States, 02114”; “Rochester, Minnesota, United States, 55905”; “New York, New York, United States, 10021”; “Canton, Ohio, United States, 44718”; “Portland, Oregon, United States, 97239”; “Houston, Texas, United States, 77030” |
| France | “Clichy, Île-de-France Region, France, 92110” |
| Netherlands | “Rotterdam, South Holland, Netherlands, 3015” |
| Switzerland | “Basel, Canton Basel-Stadt, Switzerland, CH-4001” |
| United Kingdom | “Saint Johns Wood, London, United Kingdom, NW3 2QG”; “Withington, Manchester, United Kingdom, M20 4BX” |

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.2-4"></a>

#### European member states, trial dates, and recruitment status in the EU Clinical Trials Information System record

> “Locations France, Netherlands”
> “Start of trial 10/03/2026”
> “Ongoing, recruitment ended”
> “Estimated recruitment start date in EU/EEA: 08/09/2025”
> “Estimated end of trial date in EU/EEA: 09/09/2030”
> “Estimated global end date of the trial: 10/09/2030”

Source: [EU Clinical Trials Information System 2024-515447-36-00](https://euclinicaltrials.eu/ctis-public/view/2024-515447-36-00)

<a id="topic-3.1.1.2-5"></a>

#### Planned conduct primarily in the United States at IND clearance

> “The Company is initiating start-up activities for the study which will be primarily conducted in the U.S. and patient enrollment is planned to commence in the first half of 2025.”

Source: [Rezolute tumor HI IND clearance release (2024)](https://ir.rezolutebio.com/news/detail/337/rezolute-announces-fda-clearance-of-ind-application-for-phase-3-registrational-study-of-rz358-for-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)

<a id="topic-3.1.1.2-6"></a>

#### Enrollment in the United States and Europe at fiscal year end 2026

> “The upLIFT study in tumor HI is currently enrolling in the U.S. and Europe.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-3.1.1.2-7"></a>

#### Completion of enrollment and expected topline timing

> “today announced that the open-label Phase 3 study of ersodetug in tumor HI (upLIFT) is now fully enrolled and topline data are expected mid-December 2026.”

Source: [Rezolute upLIFT enrollment completion release (2026)](https://ir.rezolutebio.com/news/detail/386/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.2-8"></a>

#### Study initiation and current status in the quarterly report

> “The study is now fully enrolled and topline data is expected in mid-December 2026.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-3.1.1.2-9"></a>

#### Timing of results for the completed study

> “Results for the completed study, including statistical analysis of the primary endpoint, are expected by mid-December 2026.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Official title in the ClinicalTrials.gov record

> “A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients With Inadequately Controlled Hypoglycemia Due to Tumor Hyperinsulinism (Tumor HI)”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.3-2"></a>

#### Allocation, intervention model, and masking in the ClinicalTrials.gov record

> “Interventional Model : Single Group Assignment”
> “Masking : None (Open Label)”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.3-3"></a>

#### Study periods in the ClinicalTrials.gov record

> “The study is divided into 3 periods: Screening (up to 4 weeks), Treatment (8 weeks) and either End of Study Follow-up (approximately up to 20 weeks after the last dose) or optional Open Label Extension (OLE) phase (up to 3 years).”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.3-4"></a>

#### Current single-arm, open-label design described by the company

> “The upLIFT Phase 3 registrational study is a single-arm, open-label, pivotal trial in approximately 16 participants with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor hyperinsulinism (HI).”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.3-5"></a>

#### Multicenter design in the corporate presentation

> “Global, multi - center, single - arm, open - label registrational study”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-3.1.1.3-6"></a>

#### Original randomized, placebo-controlled design at IND clearance

> “The Phase 3 registrational study is a double-blind, randomized, placebo-controlled trial of 24 participants who have inadequately controlled hypoglycemia because of tumor HI.”
> “Up to 24 additional participants may be enrolled into an open-label arm, in participants whose hypoglycemia is being managed by IV glucose in a hospital setting.”
> “The primary endpoint is the change in Level 2 (moderate) and Level 3 (severe) hypoglycemia events by self-monitored blood glucose.”

Source: [Rezolute tumor HI IND clearance release (2024)](https://ir.rezolutebio.com/news/detail/337/rezolute-announces-fda-clearance-of-ind-application-for-phase-3-registrational-study-of-rz358-for-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)

<a id="topic-3.1.1.3-7"></a>

#### Design change agreed with the FDA in August 2025

> “At a meeting held with FDA on August 19, 2025, the agency agreed to modifications to the design of the study including removing the need to conduct a double-blind randomized placebo-controlled trial.”
> “The truncated study will include as few as 16 participants and will be limited to the single-arm open-label portion of the upLIFT study, which has been the focus of the Company’s patient recruitment efforts.”

Source: [Rezolute upLIFT design alignment release (2025)](https://ir.rezolutebio.com/news/detail/361/rezolute-announces-alignment-with-fda-on-streamlined-design-for-ongoing-phase-3-trial-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.3-8"></a>

#### Removal of the hypoglycemia event endpoint in the annual report

> “At a meeting held with FDA on August 19, 2025, the Agency agreed to modifications to the design of the upLIFT study including removing the need to conduct a randomized, double-blind, placebo-controlled trial with hypoglycemia events as the endpoint.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

> “The eligibility criteria of all participants must be evaluated by a multidisciplinary team led by the PI, which must include an oncologist”
> “Male or female participants of ≥18 years of age who provide written informed consent.”
> “Clinical diagnosis of neuroendocrine tumor (NET) (ICT or NICT) with biochemical evidence of tumor hyperinsulinism (hypoglycemia with inappropriately elevated insulin or insulin-like growth factor (IGF)/variant suppression) confirmed via laboratory assessment who have failed to achieve adequate control of hypoglycemia with usual SOC anti-hypoglycemic therapies, per investigator judgement.”
> “Currently requiring IV glucose infusion and/or parenteral nutrition for ≥7 days for the management of refractory hypoglycemia (prior to administration of the 1st dose of ersodetug).”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.4-2"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Evidence of active infection including human immunodeficiency virus, hepatitis B, or hepatitis C (excluding immunization patterns).”
> “Treatment with an investigational drug or device within 30 days or 5 half-lives of the investigational drug (whichever is longer), however, if the treating physician and Medical Monitor consider no significant risk of drug-drug interaction and potential benefit outweighs the risk then the participant may be allowed to participate.”
> “Any out-of-range laboratory value at screening (other than glucose) that is assessed as clinically significant by the investigator.”
> “Known allergy or sensitivity to ersodetug or any component of the drug.”
> “Estimated life expectancy (additional lifespan) due to underlying disease (tumor) is <8 weeks.”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.4-3"></a>

#### Age and sex eligibility in the ClinicalTrials.gov record

> “Ages Eligible for Study 18 Years and older (Adult, Older Adult )”
> “Accepts Healthy Volunteers No”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.4-4"></a>

#### Requirement for continuous parenteral dextrose described by the company

> “The streamlined upLIFT study is a Phase 3, registrational, single-arm, open-label, pivotal trial in approximately 16 participants with insulinoma or paraneoplastic non-islet cell tumors, who require continuous parenteral dextrose because of refractory hypoglycemia.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

Additional sources: [EU Clinical Trials Information System 2024-515447-36-00](https://euclinicaltrials.eu/ctis-public/view/2024-515447-36-00)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Arm and intervention in the ClinicalTrials.gov record

> “Ersodetug (9 mg/kg) + SOC”
> “Every study participant will receive ersodetug doses weekly for 8 weeks alongside their usual treatments for hypoglycemia at a dose of 9 mg/kg.”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.5-2"></a>

#### Pivotal dosing and extension dosing frequency

> “Eligible participants requiring continuous parenteral dextrose will receive ersodetug 9 mg/kg per week for 8 weeks, as an add-on to standard of care.”
> “Following this 8-week pivotal treatment period, all participants may receive ersodetug in long-term extension, with the discretion to decrease the dosing frequency to every 2 to 4 weeks.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-3.1.1.5-3"></a>

#### Dosing described in the results release

> “Eligible participants requiring continuous intravenous (IV) glucose receive ersodetug 9 mg/kg per week for 8 weeks, as an add-on to standard of care.”
> “Following this 8-week pivotal treatment period, all participants may receive ersodetug at a reduced dosing frequency in long-term extension.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.5-4"></a>

#### Once-weekly administration in the corporate presentation

> “Once weekly administration of 9 mg/kg per week as add on to SOC over 8 - week pivotal treatment period”
> “All participants may receive ersodetug in long - term extension”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Glucose Infusion Rate Reduction of at Least 50% as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “Proportion of participants with clinically meaningful reduction in IV glucose infusion rate from baseline.” | “8 weeks” |
| Secondary | “Change from baseline in average daily IV glucose/dextrose infusion rate (GIR).” | “8 weeks” |
| Secondary | “Change from baseline in average daily total IV glucose delivery (g)” | “8 weeks” |
| Secondary | “Time to complete weaning off IV glucose administration after initiating ersodetug.” | “8 weeks” |

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.6.1-2"></a>

##### Primary endpoint and additional endpoints defined by the company

> “The primary endpoint is the proportion of participants able to achieve at least a 50 percent reduction from baseline in GIR, a measure of intravenous glucose dependency for underlying hypoglycemia.”
> “Additional endpoints include the number of participants achieving complete discontinuation of GIR and time to discontinuation, time to discharge from the hospital as applicable, extent of hypoglycemia events and hypoglycemia time in the outpatient setting by self-monitored blood glucose and continuous glucose monitor, respectively, and patient reported quality of life.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.6.1-3"></a>

##### Responder window within the pivotal treatment phase

> “The study’s primary endpoint is the percent of participants who require intravenous glucose for refractory hypoglycemia that achieve at least a 50 percent reduction from baseline in glucose infusion rate (GIR) within the 8-week pivotal treatment phase.”

Source: [Rezolute upLIFT enrollment completion release (2026)](https://ir.rezolutebio.com/news/detail/386/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.6.1-4"></a>

##### Functional status among additional endpoints in the corporate presentation

> “Additional endpoints for GIR, time to discharge from the hospital, and extent of hypoglycemia in the outpatient setting, ECOG status, and patient reported quality of life”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-3.1.1.6.1-5"></a>

##### Glucose infusion rate as an objective endpoint measured in hospital

> “Notably, the GIR assessment in the EAP is the primary endpoint in upLIFT, which measures the number of participants (out of ~16) who achieve at least a 50% reduction in GIR, an objective endpoint in a highly controlled hospital setting.”
> “For statistical significance, 9 of 16 open-label participants need to achieve this threshold.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.6.1-6"></a>

##### Expanded access data that informed the endpoint and the design revision

> “This same data cohort was provided to FDA last year in support of the Company’s request for Breakthrough Therapy Designation and subsequently informed the discussion with FDA that led to revision of the Phase 3 upLIFT study in tumor HI to a single arm, open-label study.”
> “In summary, 75% of the patients receiving IV dextrose/total parenteral nutrition (TPN) in the EAP achieved a complete discontinuation of IV dextrose/TPN.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.6.1-7"></a>

##### Basis for the streamlined design stated by the company

> “The FDA’s staff and leadership have been very vocal about the desire to responsibly simplify clinical development for rare diseases, particularly when there is real-world evidence of benefit combined with mechanistic plausibility.”
> “We believe that the alignment we have achieved with the agency exemplifies this innovative approach and is substantially based upon the favorable outcomes that we have observed over the last two years treating more than 10 patients with tumor HI under our Expanded Access Program.”

Source: [Rezolute upLIFT design alignment release (2025)](https://ir.rezolutebio.com/news/detail/361/rezolute-announces-alignment-with-fda-on-streamlined-design-for-ongoing-phase-3-trial-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.6.1-8"></a>

##### Design modification to improve the likelihood of demonstrating efficacy

> “In an effort to align with FDA guidance and improve the likelihood of demonstrating efficacy, the FDA allowed us to modify the upLIFT trial design.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-3.1.1.6.1-9"></a>

##### Glucose infusion rate assessment contrasted with self-monitored measures in sunRIZE

> “These results reveal the clinically impactful hypoglycemia-correcting activity of ersodetug in an unbiased GIR assessment in patients with HI caused by varying tumor types.”
> “This further highlights the aberrant outcome from the recently completed randomized, placebo-controlled, Phase 3 sunRIZE study in pediatric congenital HI, where we believe that self-monitored glycemic measures were confounded by divergent caretaker behaviors stemming from functional unblinding to treatment status by real-time glucose monitoring.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.6.1-10"></a>

##### Clinical relevance of parenteral glucose dependence in tumor hyperinsulinism (insulinoma)

> “Supportive strategies such as frequent carbohydrate intake or continuous parenteral dextrose infusion are often required but are burdensome and do not provide durable control, and parenteral infusions may prevent hospital discharge.”
> “Assessments of efficacy focused on changes in GIR (since most participants initially required parenteral dextrose to correct refractory hypoglycemia) and also included assessments of hypoglycemia by CGM (described below), number of hospitalization days in the month before and after ersodetug initiation, and overall survival.”
> “Most individuals were receiving parenteral dextrose during baseline, which by intent likely ameliorated hypoglycemia, thus masking the severity of baseline glycemic measures by CGM.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.1.6.1-11"></a>

##### Success threshold of a lower 95% confidence bound above 30%

> “where statistical significance would be achieved if the lower bound of the 95% confidence interval of the point estimate exceeds 30% (equating to a responder rate of ~9 of 16 participants)”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-3.1.1.6.1-12"></a>

##### Agreement with the FDA on an adequate and well-controlled program

> “Alignment with FDA on tumor HI clinical data package which support BLA filing, including a streamlined yet adequate and well - controlled Phase 3 clinical program”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

Additional sources: [EU Clinical Trials Information System 2024-515447-36-00](https://euclinicaltrials.eu/ctis-public/view/2024-515447-36-00)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 16”
> “The study will enroll approximately 16 participants, all with a diagnosis of tumor HI (insulin- or IGF producing tumors).”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-3.1.1.7.1-2"></a>

##### Enrollment of 16 participants at study completion of enrollment

> “The upLIFT study is a single-arm, open-label, registrational study in 16 participants with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor HI.”

Source: [Rezolute upLIFT enrollment completion release (2026)](https://ir.rezolutebio.com/news/detail/386/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.7.1-3"></a>

##### Participants included in the preliminary primary endpoint evaluation

> “To date, 13 participants have met the responder criterion, including 12 who also achieved a complete discontinuation of IV glucose.”
> “Three participants are still in the pivotal period of the study, including two who have not yet met the responder criterion.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.7.1-4"></a>

##### Criterion for statistical significance of the responder proportion

> “To achieve statistical significance for the endpoint, the lower bound of the 95% confidence interval for percent of patients responding must exceed 30%, which equates to at least 9 responders (≥56%), based on enrollment of 16 participants.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.7.1-5"></a>

##### Responder rate and confidence interval required for 16 participants

> “For statistical significance, the lower bound of the 95% confidence interval (CI) for the percent responder rate must be ≥30%, equating to a response rate of at least 56% (95% CI of 30-80%) for 16 participants.”

Source: [Rezolute upLIFT enrollment completion release (2026)](https://ir.rezolutebio.com/news/detail/386/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Classification of the participant who entered hospice as a non-responder

> “The reduction and eventual discontinuation of intravenous glucose were undertaken in the setting of hospice transition, so the participant is being counted as a non-responder for purposes of assessing the primary endpoint.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.7.2-2"></a>

##### Denominator of 16 enrolled participants for the significance threshold

> “To achieve statistical significance for the endpoint, the lower bound of the 95% confidence interval for the percent of patients responding must exceed 30%, which equates to at least 9 responders (≥56%), based on enrollment of 16 participants.”

Source: [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm)

<a id="topic-3.1.1.7.2-3"></a>

##### Final statistical analysis pending after the preliminary evaluation

> “The results announced to date are preliminary, are based on data evaluation that”
> “precedes completion of the study, and remain subject to change based on the completed study data and final statistical analysis.”

Source: [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Preliminary disposition at the November 2026 data evaluation

> “Three participants are still in the pivotal period of the study, including two who have not yet met the responder criterion.”
> “As previously reported, one participant discontinued the study early and chose to enter home hospice care, and died one week later due to cancer progression.”
> “This participant has been classified as a non-responder for purposes of the primary endpoint.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.1-2"></a>

##### Withdrawal of the participant with stage 4 colon cancer at the interim update

> “One of the 8 enrolled participants withdrew study consent and discontinued ersodetug and all other non-palliative therapies prior to completion of the pivotal treatment phase.”
> “This patient had Stage 4 metastatic colon cancer and a poor Eastern Cooperative Oncology Group performance status (ECOG 4).”
> “The participant elected to be discharged from the hospital to receive hospice care at home, where they died one week later due to cancer progression.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.1-3"></a>

##### Continuation into the open-label extension at the interim update

> “All participants that have completed the 8-week pivotal treatment period have elected to continue into the open-label extension, with a cumulative treatment duration of up to 6 months.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Tumor types of the 16 enrolled participants (insulinoma and non-islet cell tumor)

> “The 16 enrolled participants include four with non-islet cell tumors and 12 with insulin-secreting malignant islet cell tumors (insulinomas).”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.2-2"></a>

##### Mechanism of hypoglycemia in the enrolled participants

> “Of the 16 enrolled participants, four were experiencing hypoglycemia due to paraneoplastic secretion of IGF-2 variants from non-islet cell tumors, and the remainder were due to insulin-secreting malignant islet cell tumors (insulinomas).”

Source: [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm)

<a id="topic-3.1.1.8.2-3"></a>

##### Tumor types of the first 8 participants at the interim update

> “With 8 participants enrolled in upLIFT to date, comprising both insulinoma and non-islet cell tumor hypoglycemia, the Company is midway through enrollment of the planned study sample size of 16 participants.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Preliminary primary endpoint result at the November 2026 data evaluation

> “today announced positive results from the ongoing open-label Phase 3 upLIFT study of ersodetug in tumor HI, in which the primary efficacy endpoint has been achieved”
> “To date, 13 participants have met the responder criterion, including 12 who also achieved a complete discontinuation of IV glucose.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.3-2"></a>

##### Preliminary results subject to change before the final analysis

> “Although the primary efficacy endpoint has been achieved based on preliminary results, these results may change upon completion of the study”
> “Three participants remain in the pivotal period of the study, including two who have not yet met the responder criterion, and the final proportion of responders, and the lower bound of the 95% confidence interval for that proportion, may differ from the results announced to date.”

Source: [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm)

<a id="topic-3.1.1.8.3-3"></a>

##### Preliminary interim result in the first 8 participants (June 2026)

> “Of the 8 participants enrolled, 6 have already met the responder criterion for the study’s primary endpoint, which is the number of participants achieving at least a 50 percent reduction from baseline in intravenous glucose requirements (glucose infusion rate; GIR) within the 8-week pivotal treatment phase.”
> “Each of these 6 participants also achieved a complete discontinuation of intravenous glucose requirements with the administration of ersodetug.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.3-4"></a>

##### Preliminary update of the first 8 participants to 7 responders

> “Earlier this year, the Company announced that 7 of the 8 participants enrolled in the first half of the study met the responder criterion for the study’s primary endpoint.”
> “Furthermore, each of these participants also achieved complete discontinuation of intravenous glucose with the administration of ersodetug.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Preliminary safety in the pivotal and extension phases (November 2026)

> “Ersodetug has been well-tolerated to date in the pivotal and extension phases of the study, with no drug-related safety findings attributed to ersodetug.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.5-2"></a>

##### Preliminary drug-related adverse events stated in the prospectus supplement

> “Ersodetug has been well-tolerated to date in the pivotal and extension phases of the study, with no drug-related adverse events or other safety findings attributed to ersodetug.”

Source: [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm)

<a id="topic-3.1.1.8.5-3"></a>

##### Preliminary safety at the interim update (June 2026)

> “Ersodetug has been well-tolerated in the pivotal and extension phases of the study, with no drug-related adverse events or other safety findings reported to date.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.1.8.5-4"></a>

##### Death due to cancer progression after withdrawal to hospice

> “The participant elected to be discharged from the hospital to receive hospice care at home, where they died one week later due to cancer progression.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

- Design: upLIFT is a single-arm, open-label trial of 16 participants with no concurrent comparator, so the responder proportion is judged against a prespecified threshold (lower bound of the 95% confidence interval above 30%). The source documents word the threshold as “must exceed 30%” and as “must be ≥30%”.
- Status of the data: the results are preliminary and come from company press releases and SEC filings; no publication, congress presentation, or registry results exist. At the 13 November 2026 evaluation, 3 participants remained in the pivotal period, and the final responder proportion and its confidence interval may differ.
- Applicability: participants are adults who require IV glucose or parenteral nutrition despite standard-of-care therapies, with the primary endpoint measured in a hospital setting, and receive ersodetug as an add-on; the results describe the most severe presentation. Results by tumor type (insulinoma or non-islet cell tumor) and patient-reported quality of life have not been reported.
- One participant with stage 4 metastatic colon cancer withdrew to hospice and was counted as a non-responder; outcomes in participants with poor performance status are therefore represented by a single case.
- Registry records lag the company: ClinicalTrials.gov still lists the trial as recruiting, while the company reports enrollment complete.

Source: [Rezolute upLIFT enrollment completion release (2026)](https://ir.rezolutebio.com/news/detail/386/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism); [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism); [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm); [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm); [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism); [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
